Updated on: 28 September 2021

1. Financial interests

a) Received research funding: any grant, contract or gift, commissioned research, or fellowship from The Cochrane Collaboration or a related organisation (i.e. any organisation related to health care or medical research) to conduct research?
Yes - No funding received for the work of the Cochrane IPD MA Methods Group Funding from The Cochrane Collaboration for work to identify effective and ineffective interventions in Cochrane Reviews (2018 to present, ??9600/year). Other grants Aug 2021 to Jul 2024 (chief investigator) Fund for actioning the Northern Ireland Clinical Research Recovery, Resilience and Growth Implementation Plan: ??3,000,000 from the Department of Health and Social Care (Northern Ireland) Feb 2021 to Apr 2025 (co-investigator) Mucoactive drugs for acute respiratory failure: A 2x2 factorial, randomised, controlled, allocation concealed, open-label, Phase 3, pragmatic, clinical and cost effectiveness trial with internal pilot ??1,929,723 from National Institute of Health Research (NIHR) Health Technology Assessment (HTA) programme May 2020 to May 2021 (co-investigator) DIAMONDS: DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser (DIAMONDS) [extension] ??88,580 from NIHR HTA programme 2018 to 2020 (co-applicant) Anticipatory care planning intervention for older adults at risk of functional decline ??464,178 from CHITIN [European Union] 2018 to 2019 (co-applicant) Network analysis of stakeholders involved in the development and implementation of a national action plan in Turkey to tackle non-communicable diseases (NCDs) among Syrian refugees ??34,860 from Department for Employment & Learning, Global Challenges Research Fund [GCRF] 2017 to 2025 (co-investigator) CHAMP: Childhood Atropine for Myopia Progression ??800,600 NIHR Efficacy and Mechanism Evaluation (EME) programme 2017 to 2021 (co-investigator) A-Stop: Antifungal stewardship opportunities with rapid tests for fungal infection in critically-ill patients ??1,524,591 from NIHR HTA 2017 to 2020 (chief investigator) HSC Statistical and Methodological Research Support Service ??150,000 from Health and Social Care (Northern Ireland) Research and Development 2017 to 2020 (co-investigator) CLEAR: A 2x2 factorial randomised single blind open labelled trial to determine the clinical and cost effectiveness of hypertonic saline and carbocysteine versus usual care over 12 months in non-cystic fibrosis bronchiectasis ??985,718 from NIHR HTA 2017 to 2020 (co-investigator) ???The JACK Trial??? A multi-site cluster randomised trial of an interactive filmbased intervention to reduce teenage pregnancy and promote positive sexual health ??1,024,556 from NIHR Public Health Research (PHR) programme 2017 to 2020 (co-investigator) SANDWICH: Sedation and weaning in children: the SANDWICH trial ??1,773,962 from NIHR HTA 2017 to 2018 (chief investigator) Practical Workshop for Clinical Trials ??23,050 from British Council Newton Fund Workshops 2016 to 2018 (co-investigator) Advance care planning with older patients who have end-stage kidney disease: Feasibility of a deferred entry randomised controlled trial incorporating a mixed methods process evaluation ??145,103 from Dunhill Medical Trust Aug 2016 (principal investigator) Evidence Aid (unrestricted grant) US$65,000 from Lambert Family Foundation Apr 2016 to Aug 2016 (co-investigator) Jack Trial Intervention: refinement of the parental component ??35,742 from Health and Social Care (Northern Ireland) Research and Development Aug 2021 to Jul 2024 (chief investigator) Fund for actioning the Northern Ireland Clinical Research Recovery, Resilience and Growth Implementation Plan: ??3,000,000 from the Department of Health and Social Care (Northern Ireland) Feb 2021 to Apr 2025 (co-investigator) Mucoactive drugs for acute respiratory failure: A 2x2 factorial, randomised, controlled, allocation concealed, open-label, Phase 3, pragmatic, clinical and cost effectiveness trial with internal pilot ??1,929,723 from National Institute of Health Research (NIHR) Health Technology Assessment (HTA) programme May 2020 to May 2021 (co-investigator) DIAMONDS: DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser (DIAMONDS) [extension] ??88,580 from NIHR HTA programme 2018 to 2020 (co-applicant) Anticipatory care planning intervention for older adults at risk of functional decline ??464,178 from CHITIN [European Union] 2018 to 2019 (co-applicant) Network analysis of stakeholders involved in the development and implementation of a national action plan in Turkey to tackle non-communicable diseases (NCDs) among Syrian refugees ??34,860 from Department for Employment & Learning, Global Challenges Research Fund [GCRF] 2017 to 2025 (co-investigator) CHAMP: Childhood Atropine for Myopia Progression ??800,600 NIHR Efficacy and Mechanism Evaluation (EME) programme 2017 to 2021 (co-investigator) A-Stop: Antifungal stewardship opportunities with rapid tests for fungal infection in critically-ill patients ??1,524,591 from NIHR HTA 2017 to 2020 (chief investigator) HSC Statistical and Methodological Research Support Service ??150,000 from Health and Social Care (Northern Ireland) Research and Development 2017 to 2020 (co-investigator) CLEAR: A 2x2 factorial randomised single blind open labelled trial to determine the clinical and cost effectiveness of hypertonic saline and carbocysteine versus usual care over 12 months in non-cystic fibrosis bronchiectasis ??985,718 from NIHR HTA 2017 to 2020 (co-investigator) ???The JACK Trial??? A multi-site cluster randomised trial of an interactive filmbased intervention to reduce teenage pregnancy and promote positive sexual health ??1,024,556 from NIHR Public Health Research (PHR) programme 2017 to 2020 (co-investigator) SANDWICH: Sedation and weaning in children: the SANDWICH trial ??1,773,962 from NIHR HTA 2017 to 2018 (chief investigator) Practical Workshop for Clinical Trials ??23,050 from British Council Newton Fund Workshops 2016 to 2018 (co-investigator) Advance care planning with older patients who have end-stage kidney disease: Feasibility of a deferred entry randomised controlled trial incorporating a mixed methods process evaluation ??145,103 from Dunhill Medical Trust Apr 2016 to May 2020 (co-investigator) DIAMONDS: DIAbetic Macular Oedema aNd Diode Subthreshold micropulse laser ??893,461 from NIHR HTA Sep 2015 to Aug 2018 (principal investigator) Evidence Aid ???545,000 from C&A Foundation Jul 2015 to Jun 2020 (co-applicant) Irish Primary Care Trials Network (IPC Trials Network) ???2,499,652 from Health Research Board Apr 2015 to Mar 2018 (co-investigator) Is it possible to develop a complex intervention to improve the outcome of critically ill patients with delirium? ??150,350 from Health and Social Care (Northern Ireland) Research and Development Feb 2015 to Dec 2018 (co-applicant) EASI-SWITCH: Early switch to oral antibiotics in patients with low risk neutropenic sepsis ??1,016,416 from NIHR

b) Had paid consultancies: any paid work, consulting fees (in cash or kind) from a related organisation?
No

c) Received honoraria: one-time payments (in cash or kind) from a related organisation?
No

d) Served as a director, officer, partner, trustee, employee or held a position of management with a related organisation?
Yes - Chair of the Board of Trustees, Evidence Aid

e) Possessed share-holdings, stock, stock options, equity with a related organisation (excludes mutual funds or similar arrangements where the individual has no control over the selection of the shares)?
No

f) Received personal gifts from a related organisation?
No

g) Had an outstanding loan with a related organisation?
No

h) Received royalty payments from a related organisation?
No

2. Do you have any other competing interests that could pose a conflict of interest that would reasonably appear to be related to the primary interest?
No